OR-LATTICE-SEMICONDUCTOR
23.6.2021 18:02:13 CEST | Business Wire | Press release
Lattice Semiconductor Corporation (NASDAQ: LSCC), the low power programmable leader, today launched the Lattice CertusPro™-NX general purpose FPGA family. As the fourth device family based on the Lattice Nexus™ platform to be launched in just 18 months, CertusPro-NX continues Lattice’s commitment to FPGA innovation with leadership power efficiency, the highest bandwidth in the smallest form factor in comparison to similar devices, and as the only FPGAs in their class with support for LPDDR4 external memory. With advanced performance capabilities and the highest logic density currently available on a Nexus-based device, CertusPro-NX FPGAs are designed to accelerate application development for the Communications, Compute, Industrial, Automotive, and Consumer markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005270/en/
“Many Edge devices require low power consumption for better thermal management, high system bandwidth for fast chip-to-chip communication, components with small form factors for compact device designs, robust memory resources to support data processing, and high reliability for mission-critical applications,” said Linley Gwennap, Principal Analyst at The Linley Group. “Lattice’s CertusPro-NX FPGAs address all of these factors; in particular, they far exceed the competition in mean time between failures (MTBF) and offer the lowest power in their class.”
“At Lattice, we are constantly looking for ways to innovate and design products based on the needs of our customers, and Lattice CertusPro-NX FPGAs are the latest example of how we’re delivering on this commitment,” said Gordon Hands, Senior Director of Product Marketing, Lattice Semiconductor. “The performance and differentiated features we’ve designed into CertusPro-NX deliver capabilities that were previously unavailable in low power FPGAs to support the next generation of Edge applications that OEMs are eager to provide to customers.”
CertusPro-NX FPGAs are designed to enable customer innovation in a wide range of applications, including data co-processing in intelligent systems, high-bandwidth signal bridging in 5G communications infrastructure, and sensor interface bridging in ADAS systems. Key features of the Lattice CertusPro-NX FPGA family include:
- Class-leading power efficiency – By leveraging Lattice’s innovations in FPGA fabric architecture and a low power FD-SOI manufacturing process, CertusPro-NX devices deliver exceptional performance while consuming up to four times less power than competing FPGAs of a similar class.
- Best-in-class system bandwidth – With support for up to eight programmable SERDES lanes capable of speeds up to 10.3 Gbps, CertusPro-NX FPGAs deliver the highest system bandwidth in their class to enable popular communication and display interfaces like 10 Gigabit Ethernet, PCI Express, SLVS-EC, CoaXPress, and DisplayPort.
- Optimized Edge processing – To meet demand for robust data co-processing in Edge AI and ML applications, CertusPro-NX FPGAs feature up to 65 percent more available on-chip memory than other similar FPGAs. CertusPro-NX devices are the only low power FPGAs currently supporting the LPDDR4 DRAM memory standard, which is preferred due to its projected long-term availability.
- High logic density - With support for up to 100k logic cells, CertusPro-NX FPGAs currently offer the highest logic density of any Nexus-based FPGA.
- Industry-leading reliability – Mission-critical automotive, industrial, and communications applications must deliver high availability to enable predictable performance and keep users safe. Thanks to innovations in the Lattice Nexus platform, CertusPro-NX devices are up to 100 times more resistant to soft errors.
- Smallest-in-class form factor – With a design footprint of 81 mm2 , CertusPro-NX FPGAs are up to 6.5 times smaller than competing devices. Small form factor is a key design consideration for developers of industrial cameras or the SFP modules used in communication systems.
CertusPro-NX is compatible with the latest version of the Lattice Radiant® design software also announced today. Lattice has already shipped CertusPro-NX samples to select customers. For more information about the technologies mentioned above, please visit:
- www.latticesemi.com/CertusPro-NX
- www.latticesemi.com/LatticeNexus
- www.latticesemi.com/LatticeRadiant
About Lattice Semiconductor
Lattice Semiconductor (NASDAQ: LSCC) is the low power programmable leader. We solve customer problems across the network, from the Edge to the Cloud, in the growing Communications, Computing, Industrial, Automotive, and Consumer markets. Our technology, long-standing relationships, and commitment to world-class support let our customers quickly and easily unleash their innovation to create a smart, secure, and connected world.
For more information about Lattice, please visit www.latticesemi.com . You can also follow us via LinkedIn , Twitter , Facebook , YouTube , WeChat , Weibo , or Youku .
Lattice Semiconductor Corporation, Lattice Semiconductor (& design), and specific product designations are either registered trademarks or trademarks of Lattice Semiconductor Corporation or its subsidiaries in the United States and/or other countries. The use of the word “partner” does not imply a legal partnership between Lattice and any other entity.
GENERAL NOTICE: Other product names used in this publication are for identification purposes only and may be trademarks of their respective holders.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005270/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
